Clinical Practice Guidelines for the management of Depression
Open accessAbstract
Participants of expert group on CPG for Depression Gautam Saha, I.D Gupta, Navendu Gaur, Tushar Jagawat, Anita Gautam, T. S Sathyanarayana Rao INTRODUCTION Depression is a common disorder, which often leads to poor quality of life and impaired role functioning. It is known to be a major contributor to the global burden of diseases and according to World Health Organization (WHO), depression is the fourth leading cause of disability worldwide and it is projected that by 2020, it will be the second most common leading cause of disability. Depression is also associated with high rates of suicidal behaviour and mortality. When depression occurs in the context of medical morbidity, it is associated with increased health care cost, longer duration of hospitalization, poor cooperation in treatment, poor treatment compliance and high rates of morbidity. Depression is also known to be associated with difficulties in role transitions (e.g., low education, high teen child-bearing, marital disruption, unstable employment) and poor role functioning (e.g., low marital quality, low work performance, low earnings). It is also reported to be a risk factor for the onset and persistence of a wide range of secondary disorders. Available data also suggests that between one-third and one-half of patients also experience recurrence of depressive episodes. ASSESSMENT AND EVALUATION (table-1)Table 1: Components of assessment and evaluationManagement of depression involves comprehensive assessment and proper establishment of diagnosis. The assessment must be based on detailed history, physical examination and mental state examinations. History must be obtained from all sources, especially the family. The diagnosis must be recorded as per the current diagnostic criteria. Depression often presents with a combination of symptoms of depressed mood, loss of interest or pleasure, decreased energy and fatigue, reduced concentration and attention, reduced self-esteem and self-confidence, ideas of guilt and unworthiness, bleak and pessimistic views of the future, ideas or acts of self-harm or suicide, disturbed sleep and diminished appetite. Depending on the severity of depression some of these symptoms may be more marked and develop characteristic features that are widely regarded as having special clinical significance. These symptoms are known as somatic symptoms of depression and include symptoms of loss of interest or pleasure in activities that are normally enjoyable, lack of emotional reactivity to normally pleasurable surroundings and events, waking up in the morning 2 hours or more before the usual time, depression worse in the morning, objective evidence of definite psychomotor retardation or agitation (remarked on or reported by other people), marked loss of appetite, weight loss (often defined as 5% or more of body weight in the past month) and marked loss of libido. It is important to note that for the diagnosis of depressive disorder these symptoms need to be present for at least 2 weeks and need to be associated with psychosocial dysfunction. Some of the patients with depression may present with predominant complaints of aches, pains and fatigue and they may not report sadness of mood on their own. A careful evaluation of these patients often reveals the underlying features of depression. However, it is important to note that many patients with depression will also have associated anxiety symptoms. With increasing severity of depression patients may report psychotic symptoms and may also present with catatonic features. Thorough assessment also ought to focus on evaluation for comorbid substance abuse/dependence. Careful history of substance intake need to be taken to evaluate the relationship of depression with substance intoxication, withdrawal and abstinence. Whenever required appropriate tests like, urine or blood screens (with prior consent) may be used to confirm the existence of comorbid substance abuse/dependence. Many physical illnesses are known to have high rates of depression. In some situations the physical illnesses have causative role in development of depression, whereas in other situations the relationship/co-occurrence is due to common etiology. Some of the physical illnesses commonly associated with depression are listed in Table-2. When depression occurs in relation to physical illness attempt may be made to clearly delineate the symptoms of depression and physical illness. Further, while making the diagnosis, it maybe clearly mentioned as to which diagnostic approach [i.e., inclusive approach (symptoms are counted whether or not they might be attributable to physical illness), substitute approach (nonsomatic symptoms are substituted with somatic symptoms), exclusive approach (somatic symptoms are deleted from the diagnostic criteria) or best estimate approach] was followed. Further, while reviewing the treatment history of medical illnesses, medication induced depression must be kept in mind, as many medic
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment-resistant depression, mania, and schizophrenia, including clozapine-resistant schizophrenia, are well-recognized indications for ECT, with evidence from comparative trials.
“Treatment-resistant depression, mania, and schizophrenia, including clozapine-resistant schizophrenia, are well-recognized indications,[1-6] with evidence from comparative trials (comparison across types of ECT or with waitlisted patients).”
From Clinical Practice Guidelines for the Use of Electroconvulsive Therapy (2023) · cites this paper as [1]
The Management of Treatment Resistance Depression section identifies ECT as an option for moderate or severe depression that has not responded to medication and reports a satisfactory response in approximately 50% of medication-resistant patients. This copy does not support the claim about mania or schizophrenia, including clozapine-resistant schizophrenia, or the stated evidence from comparisons between ECT types or with waitlisted patients. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657 · see citing works
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,150 · see citing works
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 526 · see citing works
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · see citing works
Ravindran, A., Balneaves, L., Faulkner, G., Ortiz, A., Mcintosh, D., Morehouse, R., Ravindran, L. N., Yatham, L., Kennedy, S., Lam, R. W., et al. (2018) · Focus · doi:10.1176/appi.focus.16106 · Cited by 348 · see citing works
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Ellis, P., & Australian, R. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 231 · see citing works
Parikh, S. V., Segal, Z. V., Grigoriadis, S., Ravindran, A. V., Kennedy, S. H., Lam, R. W., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.042 · Cited by 183 · see citing works
An overview of Indian research in depression
Grover, S., Dutt, A., & Avasthi, A. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69231 · Cited by 177 · see citing works
Self-citationResearch on antidepressants in India
Avasthi, A., Grover, S., & Aggarwal, M. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69263 · Cited by 18
Self-citationA systematic review and meta-analysis of trials of treatment of depression from India
Sarkar, S., & Grover, S. (2014) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.124711 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
5 of the 15 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- [1]American Psychiatry Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 2010 152
- [6]Grover S Dutt A Avasthi A Research on Depression in India Indian J Psychiatry 2010 52 Suppl S178 S188 21836676 PMC3146226
- [12]Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression Australian and New Zealand Journal of Psychiatry 2004 38 6
- [14]Singh T Rajput M Misdiagnosis of Bipolar Disorder Psychiatry (Edgmont) 2006 3 57 63 PMC2945875 20877548
Cited by
Sorted by citations
Major depressive disorder: Validated treatments and future challenges
Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i31.9350 · Cited by 201 · see citing works
Depression and Its Phytopharmacotherapy—A Narrative Review
Dobrek, Ł., & Głowacka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054772 · Cited by 160 · see citing works
ECT in schizophrenia:a review of the evidence
Grover, S., Sahoo, S., Rabha, A., & Koirala, R. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.32 · Cited by 122 · see citing works
Self-citationA proposed severity classification of borderline symptoms using the borderline symptom list (BSL-23)
Kleindienst, N., Jungkunz, M., & Bohus, M. (2020) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/s40479-020-00126-6 · Cited by 107 · see citing works
“In contrast to guidelines on the treatment of depressive disorders providing empirically informed guidance for differential treatment of mild, medium, and severe symptomatology [13], research on different levels of symptom severity of BPD is still at quite an early stage.”
ResultClinical practice guidelines for management of depression in elderly
Avasthi, A., & Grover, S. (2018) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.224474 · Cited by 99 · see citing works
Self-citationJohnson, D., Thurairajasingam, S., Letchumanan, V., Chan, K., & Lee, L. (2021) · Nutrients · doi:10.3390/nu13051728 · Cited by 112 · see citing works
Gual-Montolio, P., Jaén, I., Martínez-Borba, V., Castilla, D., & Suso-Ribera, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137737 · Cited by 93 · see citing works
“…but not psychological treatment, even though guidelines indicate that several psychological treatments, especially Cognitive Behavioral Therapy (CBT), have the highest level of evidence and may be considered as initial interventions for people with mild-to-moderate depression or anxiety [19–23].”
BackgroundForbes, D., Pedlar, D., Adler, A. B., Bennett, C., Bryant, R. A., Busuttil, W., Cooper, J. A., Creamer, M. C., Fear, N. T., Greenberg, N. L., et al. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1595545 · Cited by 95 · see citing works
“…have clearly developed heuristic definitions of treatment resistance (McFarlane, 2019) and have adopted clinical algorithms that guide clinicians through the decision-making process of ‘next steps’ when treatment is ineffective and a change of treatment plan is indicated (Gautam et al., 2017).”
Levkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health Journal · doi:10.1136/fmch-2023-002391 · Cited by 81 · see citing works
“Scrutiny and handling of gender or socioeconomic biases.”
BackgroundClinical Practice Guidelines for the Use of Electroconvulsive Therapy
Thirthalli, J., Sinha, P., & Sreeraj, V. S. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_491_22 · Cited by 74 · see citing works
Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia
Bryll, A., Skrzypek, J., Krzyściak, W., Szelągowska, M., Śmierciak, N., Kozicz, T., & Popiela, T. J. (2020) · Biomolecules · doi:10.3390/biom10030384 · Cited by 73 · see citing works
Sumiyoshi, T., Watanabe, K., Noto, S., Sakamoto, S., Moriguchi, Y., Tan, K. H. X., Hammer-Helmich, L., & Fernandez, J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.064 · Cited by 70 · see citing works
Fernández, D., Vigo, D., Sampson, N. A., Hwang, I., Aguilar-Gaxiola, S., Al-Hamzawi, A. O., Alonso, J., Andrade, L. H., Bromet, E. J., de Girolamo, G., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291720000884 · Cited by 65 · see citing works
The Psychology of Atopic Dermatitis
Courtney, A., & Su, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061602 · Cited by 66 · see citing works
“Alternative preferred options in adults include tricyclic antidepressants, mirtazapine, bupropion, and venlafaxine [44].”
BackgroundShimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.013 · Cited by 62 · see citing works
Ortega, M. A., Fraile‐Μartinez, O., Montero, C. G., Álvarez-Mon, M. Á., Lahera, G., Monserrat, J., Llavero-Valero, M., Gutiérrez-Rojas, L., Molina, R., Rodríguez–Jiménez, R., et al. (2022) · Nutrients · doi:10.3390/nu14153099 · Cited by 76 · see citing works
Pharmacokinetic considerations for current state-of-the-art antidepressants
Wyska, E. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1669560 · Cited by 60 · see citing works
MicroRNAs as critical biomarkers of major depressive disorder: a comprehensive perspective
Ortega, M. A., Alvarez-Mon, M. A., García-Montero, C., Fraile-Martinez, O., Lahera, G., Monserrat, J., Muñoz-Merida, L., Mora, F., Rodríguez-Jiménez, R., Fernandez-Rojo, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111659 · Cited by 57 · see citing works
Overcoming Depression with 5-HT2A Receptor Ligands
Zięba, A., Stępnicki, P., Matosiuk, D., & Kaczor, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010010 · Cited by 68 · see citing works
Development and implementation of guidelines for the management of depression: a systematic review
Lee, Y., Brietzke, E., Cao, B., Chen, Y., Linnaranta, O., Mansur, R. B., Cortes, P., Kösters, M., Majeed, A., Tamura, J. K., et al. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.20.251405 · Cited by 45 · see citing works
Effectiveness of common antidepressants: a post market release study
Alemi, F., Min, H., Yousefi, M., Becker, L. K., Hane, C. A., Nori, V. S., & Wojtusiak, J. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101171 · Cited by 41 · see citing works
“To help clinicians improve their prescription patterns, several consensus-based guidelines have been published [2-10].”
BackgroundBuilding Trustworthy NeuroSymbolic AI Systems: Consistency, Reliability, Explainability, and Safety
Gaur, M., & Sheth, A. P. (2023) · The AI Magazine · doi:10.48550/arxiv.2312.06798 · Cited by 41
“Incorporating clinical assessment methods (which is a component of broader clinical practice guidelines), such as PHQ-9, results in consistent outcomes when users interact with T5-XL, regardless of how they phrase their queries (Gautam et al. 2017).”
MethodHealthcare Utilization and Costs Associated With Perinatal Depression Among Medicaid Enrollees
Pollack, L., Chen, J., Cox, S., Luo, F., Robbins, C. L., Tevendale, H., Li, R., & Ko, J. Y. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.12.008 · Cited by 40 · see citing works
Understanding the schizophrenia prodrome
George, M., Maheshwari, S., Chandran, S., Manohar, J. S., & Rao, T. S. S. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_464_17 · Cited by 40
“[32] Antipsychotic medications for such people seem to be a logical extension for treatment protocol as a whole.[33-35] In a double blind, randomized, placebo controlled treatment study; patients were supplemented with omega 3 fatty acids.”
Raza, S. H., Yousaf, M., Sohail, F., Munawar, R., Ogadimma, E. C., & Siang, J. M. L. D. (2021) · Psychology Research and Behavior Management · doi:10.2147/prbm.s328416 · Cited by 57 · see citing works
Predictors of depression among Chinese college students: a machine learning approach
Luo, L., Yuan, J., Wu, C., Wang, Y., Zhu, R., Xu, H., Zhang, L., & Zhang, Z. (2025) · BMC Public Health · doi:10.1186/s12889-025-21632-8 · Cited by 39 · see citing works
“Globally, depression is one of the leading causes of disease burden, profoundly impacting individuals’ quality of life and social functioning [2, 3].”
Ghazizadeh-Hashemi, F., Bagheri, S., Ashraf-Ganjouei, A., Moradi, K., Shahmansouri, N., Mehrpooya, M., Noorbala, A., & Akhondzadeh, S. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13276 · Cited by 36 · see citing works
“depressive symptoms since these medications have better tolerability compared to other classes of antidepressants.(6) However, major challenges still remain for application of these drugs.”
BackgroundUse of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 41 · see citing works
“Antidepressant medications, such as the selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors, can be used for treatment of mild, moderate, and severe depression [6].”
BackgroundShimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.040 · Cited by 34 · see citing works
Ceylan, D., Yılmaz, S., Tuna, G., Kant, M., Er, A., Ildız, A., Verim, B., Akış, M., Akan, P., Islekel, H., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104600 · Cited by 33 · see citing works
Kuang, W.-H., Dong, Z.-Q., Tian, L.-T., & Li, J. (2018) · Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2018.02.004 · Cited by 30 · see citing works
“Depression has been regarded as a major factor in the global burden of diseases and is the 4th leading cause of disability worldwide according to the World Health Organization (WHO) [1].”
BackgroundPrevalence of depression among middle aged women in the rural area of Kerala.
Ps, A., Das, S., Philip, S., Philip, R., Joseph, J., Punnoose, V., & Lalithambika, D. P. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.05.016 · Cited by 30 · see citing works
Barbato, A., & D’Avanzo, B. (2020) · Family Process · doi:10.1111/famp.12540 · Cited by 37 · see citing works
Severe, J., Greden, J. F., & Reddy, P. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200008 · Cited by 25 · see citing works
Ceylan, D., Karaçiçek, B., Tufekci, K., Aksahin, I. C., Şenol, Ş. H., & Genç, Ş. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1304660 · Cited by 24 · see citing works
Psychosocial Interventions in Patients with Dual Diagnosis
Subodh, B., Sharma, N., & Shah, R. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_18_18 · Cited by 22 · see citing works
Xiong, J., Wang, J., Zhao, X., Yang, C., Jiang, X.-S., Chen, Y.-M., Chen, C.-Q., & Li, Z.-Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i31.9520 · Cited by 22 · see citing works
Johnson, E., Corrick, S., Isley, S., Vandermeer, B., Dolgoy, N., Bates, J., Godfrey, E., Soltys, C., Muir, C., Vohra, S., et al. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000435 · Cited by 24 · see citing works
“This is of particular relevance as CBT, while recommended in clinical practice guidelines to manage anxiety [121] and depression [122], may not be effective for all patients.”
BackgroundDeore, R., Ansari, R., Awathale, S. N., Shelke, M., Badwaik, H., Goyal, S. N., & Nakhate, K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176707 · Cited by 21 · see citing works
M, N., Patil, A. N., Pattanaik, S., Kaur, A., Banerjee, D., & Grover, S. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.101918 · Cited by 21
Self-citationHu, X.-X., Zhang, L.-Q., Hu, X.-Y., Lu, L., Tang, S., Li, H.-L., Bu, X., Gong, Q., & Huang, X.-Q. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26520 · Cited by 21 · see citing works
“Furthermore, the patients' prescriptions were in accordance with the clinical guidelines for the management of patients with MDD.43 Hence, the results of the current study reflected the reality of clinical practice and might therefore have especially strong clinical implications.”
ResultInfluentialKurnianingsih, N., Ratnawati, R., Nazwar, T., Ali, M., & Fatchiyah, F. (2021) · Medical archives · doi:10.5455/medarh.2021.75.94-100 · Cited by 20 · see citing works
“Antidepressant is an important part of depression treatment algorithm (7).”
BackgroundKumari, B., Singh, A. K., Kar, S. K., Tripathi, A., & Agarwal, V. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103637 · Cited by 25 · see citing works
More, S. M., Kaleem, M., Kharwade, R., Almutairy, A. F., Shahzad, N., Mujtaba, M. A., Taha, M., Pise, A. G., Zafar, A., & Mahmood, D. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149313 · Cited by 16 · see citing works
Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review
Prasitlumkum, N., Cheungpasitporn, W., Tokavanich, N., Ding, K. R., Kewcharoen, J., Thongprayoon, C., Kaewput, W., Bathini, T. J., Vallabhajosyula, S., & Chokesuwattanaskul, R. (2021) · Medical Sciences · doi:10.3390/medsci9020026 · Cited by 16 · see citing works
Shenoy, S., Amrtavarshini, R., Bhandary, R. P., & Praharaj, S. K. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102022 · Cited by 18 · see citing works
Navigating the Enigma: A Comprehensive Review of Idiopathic Intracranial Hypertension
Toshniwal, S., Kinkar, J., Chadha, Y., Khurana, K., Reddy, H., Kadam, A., & Acharya, S. (2024) · Cureus · doi:10.7759/cureus.56256 · Cited by 16
Crișan, C. A., Milhem, Z., Stretea, R., Țața, I.-M., Cherecheș, R. M., & Micluția, I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020306 · Cited by 17 · see citing works
Gabriel, F. C., Stein, A. T., de Melo, D. O., Henrique Fontes-Mota, G. C., dos Santos, I. B., de Oliveira, A. F., Fráguas, R., & Ribeiro, E. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051918 · Cited by 15 · see citing works
Zastrozhin, M., Skryabin, V., Smirnov, V., Petukhov, A., Pankratenko, E. P., Zastrozhina, A., Grishina, E., Ryzhikova, K., Bure, I., Golovinskii, P. A., et al. (2020) · Gene · doi:10.1016/j.gene.2020.144513 · Cited by 15 · see citing works
Zastrozhin, M., Skryabin, V., Smirnov, V., Grishina, E., Ryzhikova, K., Chumakov, E. M., Sychev, D., & Bryun, E. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0177 · Cited by 15
Public awareness, beliefs and attitude towards depressive disorders in Saudi Arabia
Aljadani, A., Alshammari, S. N., Alshammari, K. A., Althagafi, A. A., & AlHarbi, M. M. (2021) · Saudi Medical Journal · doi:10.15537/smj.2021.42.10.20210425 · Cited by 18 · see citing works
Multi-modal MRI for objective diagnosis and outcome prediction in depression
Pilmeyer, J., Lamerichs, R., Schielen, S. J. C., Ramsaransing, F., van Kranen-Mastenbroek, V. V., Jansen, J., Breeuwer, M., & Zinger, S. (2024) · NeuroImage: Clinical · doi:10.1016/j.nicl.2024.103682 · Cited by 13 · see citing works
“However, it is rarely used as a sole instrument in clinical practice (Gautam et al., 2017; Ruh ´ e et al., 2005).”
BackgroundMethodCrichton, M., Dissanayaka, T. D., Marx, W., Gamage, E., Travica, N., Bowers, A. P., Isenring, E. A., Yates, P. M., & Marshall, S. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.107941 · Cited by 14 · see citing works
Cao, B., Xu, L., Chen, Y., Wang, D., Lee, Y.-N., Rosenblat, J., Gao, X., Zhan, S., Sun, F., & McIntyre, R. (2021) · CNS Spectrums · doi:10.1017/s1092852921000171 · Cited by 12 · see citing works
Poojari, P., Khan, S., Shenoy, S., Acharya, L. D., Shetty, S., Bose, S., Pai, K., Kunhikatta, V., & Thunga, G. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102186 · Cited by 12
A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer
Rabin, E., Kim, M., Mozny, A., Cardoza, K., Bell, A., Zhai, L.-J., Bommi, P., Lauing, K. L., King, A. L., Armstrong, T., et al. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100449 · Cited by 11 · see citing works
“Each has its strengths (Schaaber et al., 1990; Kearns et al., 1982; Gibbons et al., 1993; Bagby et al., 2004; Bech, 2006; Garcia-Batista et al., 2018), shortcomings (Kearns et al., 1982; Carrozzino et al., 2020; Svanborg and Asberg, 2001), and geographical uses (Bech, 2006; Carmody et al., 2006).”
BackgroundSchizophrenia Psychosis in Women
Seeman, M. (2020) · Women · doi:10.3390/women1010001 · Cited by 11 · see citing works
Recent advances in the development of asenapine formulations
Suresh, A., Narayan, R., & Nayak, U. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1792439 · Cited by 11 · see citing works
Fusar-Poli, P., Pillinger, T., McCutcheon, R., Rangaswamy, T., Asmal, L., Singh, S. P., Oliver, D., Stefanelli, R., Crossley, N. A., Gadelha, A., et al. (2026) · World Psychiatry · doi:10.1002/wps.70066 · Cited by 10 · see citing works
Exploring cariprazine as a treatment option for varied depression symptom clusters
Pejušković, B., Munjiza-Jovanović, A., & Pešić, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1442699 · Cited by 10 · see citing works
“Current recommendations for patients who do not respond to initial antidepressant therapy (ADT) include switching to another antidepressant within the same class or to a different class, or employing a combination of antidepressants with different mechanisms of action (21, 24).”
BackgroundZastrozhin, M., Skryabin, V., Petukhov, A., Torrado, M., Pankratenko, E. P., Zastrozhina, A., Grishina, E., Ryzhikova, K., Shipitsyn, V., Bryun, E., et al. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00219-7 · Cited by 10
Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists
Álvarez-Mon, M., García-Montero, C., Fraile-Martínez, Ó., Quintero, J., Fernandez-Rojo, S., Mora, F., Gutiérrez-Rojas, L., Molina-Ruiz, R., Lahera, G., Álvarez-Mon, M., et al. (2023) · Brain Science · doi:10.3390/brainsci13020333 · Cited by 9 · see citing works
“The use of antidepressants is commonly recommended in the clinical management of MDD patients, which may be used alone or in combination with non-medical treatments such as physical activity, psychotherapy, or psychoeducation [11].”
BackgroundPsychiatric management of Patients in intensive care units
Marwale, A., Phadke, S. S., & Kocher, A. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_28_22 · Cited by 9 · see citing works
“[42] Treatment • In most patients, illness is time limited and does not require aggressive pharmacotherapy.”
Masoudi, M., Ansari, S., Kashani, L., Tavolinejad, H., Rashidi, B. H., Esalatmanesh, S., Ghazizadeh‐Hashemi, M., Noorbala, A. A., & Akhondzadeh, S. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000367 · Cited by 17 · see citing works
“The latest recommendations of the American Psychiatry Association (APA) on managing depression allows initial nonpharmacological management only in patients with nonsevere depression [American Psychiatry Association (APA), 2019]; therefore, patients with mild-to-moderate clinical depression (HDRS score: 14–17) – who d…”
BackgroundRaghuveer, P., Ransing, R. S., Kukreti, P., Mahadevaiah, M., El-Bahaey, W., Iyengar, S., Pemde, H. K., & Deshpande, S. N. (2020) · Indian Journal of Psychological Medicine · doi:10.1177/0253717620971559 · Cited by 10 · see citing works
Effects of Cang-Ai volatile oil on depressed mood and cortical excitability in human
Wei, Y., Cui, J., Fu, C., Xu, B., Shi, M., Dai, Y., Huang, X., Hai, Q., Ni, A., Chen, B., et al. (2023) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2023.100215 · Cited by 9 · see citing works
Tian, Y., Mengtao, X. U., Jingpeng, F. A. N. G., Qinxuan, W. U., Xiaoyan, Z., Fangqin, Y. A. N., & Zhixing, Q. I. N. G. (2023) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2023.02.001 · Cited by 8 · see citing works
Yeroushalmi, S., Chung, M., Bartholomew, E., Hakimi, M., & Koo, J. (2022) · Journal of dermatological treatment (Print) · doi:10.1080/09546634.2022.2152272 · Cited by 8 · see citing works
“First-line therapy for the majority of patients with major depressive disorder includes pharmacologic therapy with antidepressants and cognitive behavioral therapy (2).”
BackgroundPurohith, A., Chatorikar, S., Praharaj, S., Bhandary, R., & Sharma, P. S. V. N. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103132 · Cited by 8 · see citing works
Zastrozhin, M., Skryabin, V., Petukhov, A., Pankratenko, E. P., Grishina, E., Ryzhikova, K., Torrado, M., Shipitsyn, V., Bryun, E., & Sychev, D. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000568 · Cited by 8
“6 Four types of metabolizers have been identified on the basis of their metabolic rates7: (1) Extensive metabolizers who have the normal metabolic rate (GG “wild-type” genotype).”
BackgroundRamano, E., de Beer, M., & Roos, J. (2021) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v27i0.1612 · Cited by 8 · see citing works
Zastrozhin, Petukhov, Pankratenko, Grishina, Ryzhikova, Skryabin, Koporov, Bryun, & Sychev (2020) · Psychopharmacology bulletin · doi:10.64719/pb.4613 · Cited by 8
Narayanan, R., Dalton, J., Mccurdy, M., Issa, T., Oris, R., Tomlak, A., Lee, Y., McCall, K., Norceide, D., Mangan, J. J., et al. (2025) · European spine journal · doi:10.1007/s00586-025-08764-6 · Cited by 7 · see citing works
Johnson, D., Chua, K., Selvadurai, J., Niap, C. P. S., Thurairajasingam, S., Lee, L.-H., & Letchumanan, V. (2025) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000462 · Cited by 7
“…expertise is critical in establishing the diagnosis of MDD through a detailed assessment including history, physical and mental status examinations, with adherence to the criteria outlined in established diagnostic manuals, while also determining appropriate management strategies [12–14] .”
Sangüesa, E., Fernández-Egea, E., Concha, J., García, C., & Ribate, M. (2024) · Biomedicines · doi:10.3390/biomedicines12030597 · Cited by 7 · see citing works
“However, about 30–50% of patients receiving CLZ do not respond adequately or develop severe side effects, such as potentially fatal agranulocytosis [2,3].”
BackgroundPitanupong, J., & Aunjitsakul, W. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03527-6 · Cited by 7 · see citing works
“Currently, the treatment goals for MDD include complete elimination of symptoms, return to premorbid functioning, functional recovery, and satisfactory quality of life (QoL) [6].”
Wong, W. L. E., Sually, D., Hidalgo-Mazzei, D., Quoidbach, V., Simon, J., Boyer, P., Strawbridge, R., & Young, A. (2023) · European psychiatry · doi:10.1192/j.eurpsy.2023.2407 · Cited by 7 · see citing works
“Given its prevalence and impact, there has been much focus on improving treatment outcomes for MDD, culminating in a wide variety of well-established treatment guidelines that span primarily pharmacological and psychological interventions [2, 3].”
BackgroundAsadi, K., Abbasi-Maleki, S., & Hashjin, G. S. (2020) · Journal of Shahrekord University of Medical Sciences · doi:10.34172/jsums.2020.27 · Cited by 7 · see citing works
“Therefore, it is essential to use medications with fewer side effects or herbal remedies (2).”
BackgroundFactors associated with loss to follow-up of outpatients with depression in general hospitals
Zhang, J.-J., & Ye, C.-Y. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925595 · Cited by 7 · see citing works
Ramano, E., & de Beer, M. (2020) · Occupational Therapy in Mental Health · doi:10.1080/0164212x.2019.1663336 · Cited by 7 · see citing works
Evaluate Factors Influencing Depression in Baghdad: Using Deck-Depression Inventory
Aljuboori, S. B., Azeez, A.-J. A., Mahmood, A. A. R., Fathel, R., & Talab, H. (2019) · INNOVATIONS in Pharmacy · doi:10.24926/iip.v10i3.2036 · Cited by 7 · see citing works
“Patients with severe depression may not respond to psychotherapy, and they are at higher risk for suicide (20).”
BackgroundExercise-driven modulation of glutamatergic signaling: mechanisms and clinical implications.
Yu, C., Tyler, J. R., Elman, I., Blum, K., Lewandrowski, K., Sharafshah, A., Gold, M., Pinhasov, A., & Thanos, P. K. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.029 · Cited by 6 · see citing works
Muscarà, C., Gugliandolo, A., Mazzon, E., & Calì, G. (2025) · Antioxidants · doi:10.3390/antiox14070818 · Cited by 6 · see citing works
Nakhate, K., Deore, R., Awathale, S. N., Ansari, R., Goyal, S. N., & Bawane, P. P. (2025) · Pharmacological Research · doi:10.1016/j.prenap.2025.100310 · Cited by 6 · see citing works
Clinical practice guidelines on addressing cognitive impairment in treatable dementias
Siddiqui, M. A., Garg, S., & Tikka, S. K. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_684_24 · Cited by 7 · see citing works
“[33,34] While treatment with antidepressants remains the mainstay of management, certain antidepressants have been found to be more effective for depression associated with cognitive difficulties.”
Rajkumar, R. P. (2024) · Brain Sciences · doi:10.3390/brainsci14060543 · Cited by 7 · see citing works
“A more evidence-based approach to YBI, facilitating a rapprochement between yoga practitioners and practitioners of modern medicine, thereby avoiding the extremes of skepticism and unrealistic claims [32].”
BackgroundSafety, Tolerability, and Pharmacokinetics of Oral BI 1358894 in Healthy Japanese Male Volunteers
Yoon, J., Sharma, V., & Harada, A. (2024) · Clinical drug investigation · doi:10.1007/s40261-024-01357-z · Cited by 6
“Major depressive disorder (MDD) is a psychiatric condition characterized by depressed mood, loss of interest or pleasure, insomnia or hypersomnia, reduced concentration and attention, reduced self-confidence, and suicidal ideation [1, 2].”
Lee, J., Huh, S., Park, K., Kang, N., Yu, H., Park, H. G., Kim, Y. S., Kang, U. G., Won, S., & Kim, S. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06511-7 · Cited by 6 · see citing works
“…but also antipsychotic effects (Ali et al. 2019; Kim et al. 2018a; Petrides et al. 2015; Sinclair et al. 2019; Ward et al. 2018), and it has become a crucial part of current clinical guidelines for the management of schizophrenia (Galletly et al. 2016; Grover et al. 2017; Lee et al. 2020).”
Gil, D., Tiscar, C., Gomez, M., Felices, J., Gajate, L., Fernandez, P., Pestaña, D., & Bardi, T. (2022) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2022.02.002 · Cited by 6
“109 [2] Gautam S, Jain A, Gautam M, Vahia VN, Grover S.”
Patil, A. N., Kasudhan, K., Naveen, M., Batra, G., Chakrabarti, S., Avasthi, A., & Grover, S. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.08.016 · Cited by 6
Self-citationPharmacological management of orofacial pain – a clinician’s guide
Clark, M. V., Donnell, C., Durham, J., & Balasubramaniam, R. (2020) · Oral Surgery · doi:10.1111/ors.12542 · Cited by 6 · see citing works
D’Onofrio, A. M., Ferrajoli, G. F., Balzoni, L. M., Massetti, M., Zanzarri, A., Marano, G., Mazza, M., Koukopoulos, A. E., Kotzalidis, G. D., Moccia, L., et al. (2026) · Geriatrics · doi:10.3390/geriatrics11010013 · Cited by 4 · see citing works
“Psychotherapy is a well-established form of treatment for depression, featuring in all major guidelines [219–221].”
Sukumaran, B., S., A. V., Xavier, R. M., M., K., Krishnamurthi, S., P., A., & M, D. (2025) · Annals of Neurosciences · doi:10.1177/09727531251379157 · Cited by 5
“4,5 These variable responses are influenced by a complex interplay of genetic, physiological and environmental factors, such as age, hepatic and renal function, nutritional status and lifestyle habits.”
Psychoeducation as an adjunctive treatment for depression: a systematic review and meta-analysis
Carneiro, A., Silva, S. L. T., Souto, P., dos Santos, L. A., & Moreno, R. A. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100950 · Cited by 5 · see citing works
Pennington, E. L., Barner, J. C., Brown, C. M., Moczygemba, L., Patel, D. A., & Varisco, T. J. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.2.167 · Cited by 5 · see citing works
Mammarella, S., Giusti, L., Vecchio, S. D., Salza, A., CASACCHIA, M., & Roncone, R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1427316 · Cited by 6 · see citing works
“The different treatment choices opted for by students validate the scienti fi c literature highlighting how more severe symptoms require an increasingly practical, feasible, and fl exible treatment, which may necessitate re-evaluations and treatment modi fi cations based on the patient ’ s needs (61).”
BackgroundRahmati-Dehkordi, F., Khanifar, H., Najari, N., Tamtaji, Z., Taheri, A. T., Aschner, M., Ardestani, M. S., Mirzaei, H., Dadgostar, E., Nabavizadeh, F., et al. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04199-5 · Cited by 5 · see citing works
“MDD is diagnosed by mental status examination and clinical history which includes family, medical, and social history [40].”
Stephenson, J. J., Touya, M., Chrones, L., Pandya, S., Teng, C.-C., & Clayton, A. H. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100750 · Cited by 5 · see citing works
Importance of achieving rapid treatment response in major depressive disorder
Alva, G. (2023) · CNS Spectrums · doi:10.1017/s1092852923002213 · Cited by 5 · see citing works
“Accordingly, guidelines recommend a “start low, go slow” approach to dosing ADTs when treating patients with MDD; since most SOC ADTs typically take several weeks to achieve maximal efficacy, patients are encouraged to continue these ADTs for 6 to 8 weeks before increasing the dose or switching to another agent.(3,9)…”
Method
- Authors
- Grover, S., Gautam, S., Jain, A., Gautam, M., & Vahia, V.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Employees' State Insurance Model Hospital (IN)
- Corresponding author
- Grover, Sandeep
- ORCID
- Grover, Sandeep
- Venue
- Indian Journal of Psychiatry
- Published
- 2017
- Volume
- 59
- Issue
- 5
- Pages
- 34
- ISSN
- 0019-5545 (ISSN-L)
- PMC
- PMC5310101
- OpenAlex
- W2568301711
- Cited by
- 269
- References
- 15
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 52 · 2023: 29 · 2022: 29 · 2021: 29 · 2020: 29 · 2019: 12 · 2018: 10 · 2017: 3 · 2013: 2
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Psychiatry (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression, depression treatment, depression assessment, diagnostic criteria, somatic symptoms of depression, antidepressant treatment, antidepressant side effects, antidepressant discontinuation, antidepressant switching, antidepressant augmentation, antidepressant combination therapy, depression recurrence, relapse prevention, psychotherapy, suicide risk, comorbid depression, quality of life, role functioning, global burden of disease, health care costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review